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Abstract
Apart from stopping smoking, controlling hypertension and using statin, losing pos-
sible excess bodyweight and regular physical activity and exercise are the cornerstones 
in diabetes management. There is often need of controlling blood glucose immediately. 
Approach of ‘dynamic dose management of medications likely to cause hypoglycemia’ helps 
to control high blood glucose immediately as and when required with sulfonylurea 
or insulin and to taper off their dose later. Anti-hyperglycemic medications which are 
unlikely to cause hypoglycemia are continued to control hyperglycemia. The diagnosis 
of gestational diabetes usually made at 24-28 weeks is applicable for clinical management 
of mother and child and for possible prevention of diabetes later in the mother. From 
the public health perspectives, however, protection of the susceptible in utero popula-
tion from maternal malnutrition or clinical or subclinical hyperglycemia right from the 
time of conception itself also needs to be considered to control the diabetes epidemic at 
the population level. Campaigns and programmes for maintenance of optimal pre-preg-
nancy body weight as per the recommended body mass index of the respective popula-
tions along with regular physical activity and exercise during pregnancy are the essential 
measures available at hand to prevent the possibility of maternal hyperglycemia right 
from the early pregnancy.
Keywords: diabetes, CVD, hypertension, high blood pressure, physical activity, 
exercise, smoking, body mass index, ethnicity, hypoglycemia, acarbose, diabetes 
epidemiology, diabetes control, maternal health, pre-pregnancy weight
1. Introduction
There are now estimated 415 million adults aged 20–79 with diabetes worldwide and a fur-
ther 318 million adults are estimated to have impaired glucose tolerance [1]. About half of the 
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3.7 million deaths due to diabetes and its complications occur before the age of 70 years [2]. 
Up to 80% of deaths in type 2 diabetes are cardiovascular diseases (CVDs) related. Persons 
with impaired glucose tolerance are also almost three times more likely to develop coronary 
heart disease and other major cardiovascular events than people with normal glucose toler-
ance. In fact, CVDs alone account for nearly 30% of all deaths worldwide and 27% in low-
income and middle-income countries [3, 4]. Thus, in one hand, there is a need to prevent and 
treat diabetes, and on the other hand, considering various possible risk factors, the impaired 
glucose tolerance itself and CVDs have to be prevented both at individual and population 
levels.
This chapter will focus on the principles of management of type 2 diabetes at individual 
and population levels to consider while following the guidelines and managing diabetes 
and its epidemic. Management is defined as the act or skill of dealing with people or situa-
tions in a successful way [5]. The term management in the chapter covers clinical manage-
ment, research and public health perspectives. Public health is the practice of preventing 
disease and promoting good health within groups of people, from small communities to 
entire countries [6]. Primary prevention requires a focus on individuals known to be at 
risk for disease, i.e. the high-risk strategy with interventions focused on high-risk group, 
for example on people with glucose intolerance. A large proportion of the reductions in 
coronary heart disease mortality experienced in many high-income nations since the 1960s 
have been ascribed to the interventions in people at elevated risk [7]. However, individu-
als with markedly elevated levels of risk factors are relatively uncommon in the popula-
tion. The majority of CVD events occur in individuals with average or only mildly adverse 
levels of risk factors [7, 8]. Therefore, population-wide strategies are also essential. Health 
promotion and disease prevention strategies must embrace both high-risk and population 
strategies [7–10].
2. Prevention of CVDs and control of blood pressure (BP)
Seven modifiable well-known risk factors of atherosclerotic CVDs are high BP, glucose intol-
erance, physical inactivity, tobacco use, dyslipidemia, unhealthy diet and overweight/obesity 
(Figure 1).
2.1. High blood pressure (BP)
Hypertension is the most prevalent risk factor for development of cardiovascular and kidney 
disease. In 2008, worldwide, approximately 40% of adults aged 25 had been diagnosed with 
hypertension and its prevalence is predicted to increase by almost 60% in the next 2 decades 
[11, 12]. Hypertension is responsible for at least 45% of deaths due to heart disease and 51% 
of deaths due to stroke [11, 12]. High BP is the leading risk factor in the world especially in 
the non-industrialized countries [13]. In fact there is some increase in cardiovascular risk in 
patients with BP 120–140/80–90 (i.e. pre-hypertension) than in those with BP less than 120/80 
(i.e. normal BP) even in the general population [14]. Untreated BP <120/<80 mmHg (i.e. normal 
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BP) is considered as one of the ideal health factors for cardiovascular health [7, 8]. Programmes 
for controlling high BP in the industrialized countries achieved significant reduction in CVD 
mortality [7], and tobacco smoking including the second-hand smoke became the leading risk 
factor [13]. In many non-industrialized countries, such programmes have mostly not been 
accomplished. As a matter of fact in many such countries due to the inadequate network of 
the State supported rural and urban health centers/clinics, people often have limited access to 
blood pressure monitoring and management [15]. It is difficult for the people to regularly visit 
private clinics or to wait at the long queue in the free medical clinics of public hospitals. In 
such situations, the patients are more likely to visit hospitals late for crisis management only 
when the complications (like stroke, coronary heart diseases, kidney failure or pneumonia) 
develop [15].
2.2. Interaction of high blood pressure and glucose intolerance
Death rate due to CVD, even in the industrialized countries, seems to be on increase again par-
ticularly in the relatively younger population [8]. The emerging epidemic of glucose intoler-
ance, another CVD risk factor, seems to be adding up and interplaying with high BP. Among 
more than 3000 Euro Heart Survey patients with acute and elective coronary heart diseases, 
only about one-fourth had normal plasma glucose by the WHO criteria [16]. If the American 
Diabetes Association classification with fasting plasma glucose >5.6 mmol/L (>100 mg/Dl) 
had also been considered, the proportion of patients with glucose intolerance would perhaps 
have been more, as reported in another study in patients with acute coronary insufficiency 
[17]. There are two pertinent points to note in the interaction between high BP and glucose 
intolerance.
Firstly, hypertension is relatively more common in people with diabetes, about two times 
more in one study [18], than in those with normal plasma glucose. More than 75% of adults 
with diabetes have blood pressure (BP) levels ≥130⁄80 mmHg or are using antihypertensive 
medication [12]. Secondly, the adverse effects of higher blood pressure are more in people 
with glucose intolerance than in those with normal blood glucose. Even among people with 
systolic BP between 120 and 139 mmHg (i.e. at pre-hypertension level), CV mortality rate is 
about three times more in those with diabetes than in those without diabetes. And the risk 
is similarly high in different systolic BP ranges from normal to high levels [19]. Mortality 
is indeed increased 7.2-fold when hypertension is present in patients with diabetes [12]. 
Lowering 4 mmHg of systolic BP is more effective in reducing cardiovascular events than 
High blood 
pressure
Glucose 
intolerance
Tobacco use Physical 
inactivity
Dyslipidemia
Atherosclerotic 
cardiovascular
disease
Unhealthy diet Overweight/obesity
Figure 1. The seven modifiable risk factors of atherosclerotic cardiovascular disease.
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reducing 1 mmol/L of LDL cholesterol and is about four times more effective than lowering 
0.9% of glycated hemoglobin (HbA1c), and thus, in diabetes, BP control is more efficacious 
and more easy than lowering glucose [20].
3. Promoting cessation of smoking and tobacco use
The health effects of tobacco use, including on CVD, and various public health measures to 
control it are well known [2, 10]. Harmful tobacco products also include smokeless tobacco 
like snuff, gutkha, gul, chimo, mawa, nass, pan masala, tambaku and others [22].
4. Regular physical activity and exercise
Exercise is often classified as aerobic, strength (resistance) and flexibility exercise and each of 
them has their own utility and limitations. The common recommendation (e.g. 150 minutes 
Clinical management perspective: The current guidelines recommend to treat hypertension in type 2 diabetes to an 
systolic BP target of 130–140 mmHg and a diastolic BP target of 80 mmHg and to consider the lower targets if the 
patients are younger or when additional CV risk factors or microvascular diseases are present [21]. In the studies, the 
number of antihypertensive drugs required to achieve the systolic blood pressure around 130–140 mmHg are often 
more than two and even more than three in many patients. Treatment of hypertension in patients with diabetes is 
lucidly reviewed in the position paper of American Society of Hypertension [12].
Public health perspective: In non-industrialized countries, there is urgent need of establishing the network of 
the State supported rural and particularly urban health centers/clinics with general practitioners (preferably well 
trained with residential training in General Practice after medical graduation). It is required (i) for the comprehen-
sive longitudinal health care of the people with diabetes, hypertension, CVD and other conditions, (ii) for supervi-
sion of healthcare workers to implement various public health programs including that for hypertension and CVDs 
and (iii) to provide the State supported diagnostic facilities and antidiabetic, antihypertensive and other CVD drugs 
and antibiotics (then only it may be possible to restrict the over-the-counter sale of antibiotics and other drugs as the 
people otherwise would not have any access to such life-saving drugs) [15].
Research perspective: Study of the occurrence of CVD complications in the people with pre-hypertension level of BP 
and impaired glucose intolerance may indicate the different levels of HbA1c and BP to start antihypertensive treat-
ment. The combined presence of the subclinical or borderline hypertension and glucose intolerance (as ‘subclinical 
or borderline syndrome’) may be another CVD risk factor, as a residual risk factor of CVDs, at the population level.
Clinical management perspective: The five A’s framework (Ask, Advise, Assess, Assist, Arrange) has been devel-
oped to allow physicians to incorporate smoking cessation counseling into busy clinical practices [23]. Others have 
further added ‘Assess again’. There are various pharmacological agents available to help patients quit smoking 
and tobacco use. However, before such products were available and even now hundreds of thousands of people 
including health professionals have had stopped tobacco use once they realized the possible complications to them. 
Physicians’ priority, repeated advice and time spent on explaining its importance and its process of quitting play a 
crucial role for the motivation of the patients to quit tobacco use. Smokers who quit smoking abruptly (‘Cold Turkey’ 
method) have been reported to be successful than those who quit gradually [24]. However, the most important well-
known point, to emphasize to the patients repeatedly, is that after stopping tobacco use whether abruptly or slowly, 
it should not be used even once; otherwise the habit is likely to be resumed.
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or more of moderate-to-vigorous intensity physical activity per week, spread over at least 
3 days/week, with no more than 2 consecutive days without activity) is applicable to most 
adults and help to achieve cardiovascular fitness and other benefits. Brisk walking can be 
regularly included into the daily life. Two to three sessions/week of resistance exercise on 
non-consecutive days are also recommended [25]. Increased physical activity is effective in 
preventing diabetes, and the protective benefit is especially pronounced in persons at the 
highest risk for the disease [26]. At higher BMI, exercise is protective against diabetes and 
is dose-dependent. The prevention of diabetes and reduction of hyperglycemia in diabetes 
occur even without significant weight reduction [27]. American Diabetes Association rec-
ommends that prolonged sitting should be interrupted every 30 minutes for blood glucose 
benefits, particularly in adults with type 2 diabetes [25]. Possible physical activity even while 
seated (e.g. by leg exercise with or without sit down leg exercise machines) may also help. 
A more intensive physical activity program including at least 275 minutes per week may be 
needed to assist weight loss and avoid regain [21]. Higher levels of physical activity before 
pregnancy or in early pregnancy are associated with a significantly lower risk of developing 
gestational diabetes mellitus [28]. NICE guideline recommends women with gestational dia-
betes to take regular exercise (such as walking for 30 minutes after a meal) to improve blood 
glucose control [29]. Figure 2 summarizes the potential benefits of regular physical activity 
and exercise in relation to diabetes.
Figure 2. Potential benefits of regular physical activity and exercise in relation to diabetes.
Research perspective: Although type 2 diabetic subjects are insulin resistant, they are not resistant to the stimula-
tory effects of exercise on glucose utilization [30]. The local cellular and other metabolic adaptations could explain 
the increase in glucose utilization and improvement in the glucose tolerance in exercise and trained muscles. A 
major challenge has been to elucidate the molecules or cascade of molecules that act through insulin-independent, 
exercise-stimulated signaling pathway [30]. If such molecules produced during exercise are secreted in the blood 
and act like hormones in other tissues, organs, muscles and fat, study of the effect in the resting state by the reuse of 
serum of blood collected during exercise in the same person may give insight into such actions and the difference in 
the contents of resting and post-exercise sera may help to elucidate the molecules.
Research perspective: Many overweight older people with diabetes have knee osteoarthritis which may prevent 
them to walk freely. Exercises to strengthen the quadriceps—for example, quadriceps-setting exercise and straight-
leg raises—are effective in reducing pain and improving function in patients with knee osteoarthritis. However, 
people often may not adhere to the recommended methods of quadriceps strengthening exercises. Regular exercise 
with a bicycle ergometer in such patients can have beneficial effects not only for knee osteoarthritis but also for 
diabetes and CVD [31].
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5. Use of statin and antiplatelet therapy
The use of statin is the other core element to prevent the premature death and disability in 
diabetes. The mechanisms of beneficial effects of statins in CVD are not completely under-
stood. Some beneficial effects appear to occur independently of lowering of LDL cholesterol. 
Thus, most trials of statins and CVD outcomes tested specific doses of statins against placebo 
or other statins rather than aiming for specific LDL cholesterol goals, suggesting that the 
initiation and intensification of statin therapy should be based on risk profile [25, 32]. Before 
starting statin, lipid profile should be required at least once; a fasting sample is not routinely 
needed [32]. Antiplatelet therapy in diabetes is generally recommended for those with history 
of CVD and dual antiplatelet therapy is reasonable for up to 1 year after an acute coronary 
syndrome [25, 32].
6. Body weight as per the recommended body mass index (BMI) 
for the respective populations
The WHO 1998 Consultation on Obesity, based on classifications used in a number of past 
studies on Europids, indicated BMI of 18.5–24.9 kg/m2 as normal [34, 35]. A WHO expert con-
sultation on BMI for Asian populations concluded that Asians generally have a higher per-
centage of body fat than white people of the same age, sex and BMI and that the proportion of 
Asian people with a high risk of diabetes and CVD is substantial at BMIs lower than the exist-
ing WHO 1998 cut-off point for overweight (>24.9 kg/m2) [36]. The WHO [35], International 
Diabetes Federation and American Diabetes Association have recommended the upper limit 
of cut-off point of normal BMI for Asian people as 22.9 kg/m2 [25, 35, 37]. Similar and variables 
recommendations for different non-Caucasian populations have been made in various other 
studies, including those conducted in the Westernized ones.
These recommendations are in agreement with the actual body mass index of the popula-
tion. The adult mean BMI levels of 20–23 kg/m2 are found among the general population 
in Africa and Asia, whereas levels of 25–27 kg/m2 across North America and Europe in 
2002 [10]. The WHO consultation on BMI for Asian populations identified further potential 
public health action points along the continuum of BMI and indicated that the earlier opti-
mum population range (21–23 kg/m2) gives some intuitive consistency for policy makers 
[36]. The risk of insulin resistance and diabetes in adult increases progressively upwards 
of a BMI of 20–22 kg/m2 [10]. More than 80% of the people with diabetes live in low- and 
middle-income countries and nearly two thirds of diabetes globally are attributable to 
BMI above 21 kg/m2 [10]. In general, the risk of insulin resistance and glucose intolerance 
appears to increase once BMI starts rising above the middle of the recommended BMI for 
the population.
Research perspectives: Studies indicate that lower statin doses achieve lipid improvements in Chinese, Japanese 
and Koreans patients comparable with those observed with higher doses in Caucasians [33]. However as the mecha-
nism of action of statins may not be just related to the lowering of LDL cholesterol, the relation of such observation 
with cardiovascular events need to be studied.
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7. Antihyperglycemic medications
Type 2 diabetes is a chronic metabolic condition characterized by insulin resistance and insuf-
ficient pancreatic insulin production from beta-cell, resulting in high blood glucose levels 
[39]. Difficulty in utilizing the available insulin increases the workload of beta-cell. While 
using antihyperglycemic medications, the issues that need to be considered are shown in 
Figure 3. A few pertinent points are further discussed below.
7.1. Reduction of insulin resistance and beta-cell workload
Beta-cell failure is central to the ultimate development and progression of type 2 diabetes and 
it antedates and predicts diabetes onset and progression [40]. Subjects with normal glucose 
tolerance with 2-hour plasma glucose 120–139 mg/dL may have already lost 50% of beta-cell 
function, whereas subjects with impaired glucose tolerance with 2-hour plasma glucose 180–
199 mg/dL have lost up to 80% of beta-cell function. Thus, when the diagnosis of diabetes is 
made, the patient may have already lost 80% of their beta-cell function [41, 42]. The available 
clinical studies with appropriate protocols, however, indicate that existing therapy may not 
reverse or arrest progression of beta-cell dysfunction in type 2 diabetes [40]. Weight loss reduces 
insulin resistance and beta-cell workload and physical activity increases insulin utilization and 
also helps to reduce beta-cell workload and bodyweight. Both help to normalize the blood glu-
cose and are also useful for cardiovascular health. Promotion of physical activity and exercise 
and loss of excess bodyweight for as long as possible are the cornerstones of management in 
type 2 diabetes. Medications favoring these two aspects are preferred for as long as possible.
7.2. Risk of hypoglycemia
Hypoglycemia can manifest in different ways (Figure 4). Insulin is a known cause of hypoglyce-
mia. The risk of hypoglycemia associated with the use of other antihyperglycemic medications 
is given below [21]:
Figure 3. Factors to consider while prescribing antihyperglycemic medications in type 2 diabetes.
Research perspectives: Compared with the BMI cut point of 30.0 kg/m2 among Europeans, a similar glucose factor distri-
bution is observed at corresponding BMI cut points of 21.0 kg/m2 in South Asians, 20.6 kg/m2 in Chinese and 21.8 kg/m2 in 
Aboriginals in Canada [38]. The BMI cut points are, however, higher, for the lipid and blood pressure factors than for the 
glucose factor in South Asians, Chinese, and Aboriginals in the study [38] pointing out the need to study BMI cut points 
in different populations similarly considering the glucose, lipid and blood pressure factors separately.
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• Metformin, acarbose and other alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibi-
tor, glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibi-
tors are associated with neutral risk of hypoglycemia.
• Sulfonylurea is associated with moderate-to-severe risk and repaglinide moderate risk of 
hypoglycemia [21].
The patients only on antihyperglycemic treatment unlikely to cause hypoglycemia can check 
their glycemic control with blood glucose fasting, 2-hour postprandial glucose and HbA1c 
estimation. If the patients are also on medications, like sulfonylurea, repaglinide and insulin, 
which can cause hypoglycemia, they need to check their blood glucose also at other time 
(e.g. before meals and exercise or later in the day or at night) considering the hypoglyce-
mic symptoms and the maximum onset and duration of action of the drugs likely to cause 
hypoglycemia.
The popular guidelines cover detail aspects of different medications including the monitoring 
of glucose [21, 25, 39]. As acarbose, an alpha-glucosidase inhibitor, is increasingly used and 
has relatively longer safety profile, efficacy and other benefits, it can also be considered in 
the early phase of therapy in glucose intolerance. Four alpha-glucosidase inhibitors currently 
exist: acarbose, miglitol, voglibose and emiglitate [43]. Acarbose inhibits both alpha-amylase 
(which breaks down starch to disaccharides) and other alpha-glucosidase (which digests 
disaccharides), where as voglibose and miglitol inhibit the disaccharide-digesting enzymes 
well, but have no effect on the starch digesting enzyme alpha-amylase [44]. Acarbose and 
voglibose are minimally absorbed from the intestine and have very low bioavailability [44] 
with acarbose having less than 2% systemic availability [45]. Miglitol is almost completely 
absorbed from the upper part of the intestine [44]. Acarbose was first developed. Among the 
alpha-glucosidase inhibitors, acarbose is the most prescribed drug and most data and best-
outcomes are obtained for it [43].
Figure 4. Manifestations of hypoglycemia. Note: The patient may not volunteer the information; the healthcare 
professionals have to ask the leading questions so that the dose of the medications likely to cause hypoglycemia, viz. 
insulin, sulfonylurea and repaglinides, can be appropriately reduced.
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7.3. Acarbose
Acarbose is an effective drug with relatively long safety profile having various cardiovascu-
lar and metabolic beneficial effects, it is not associated with hypoglycemia and it promotes 
weight loss [43–48]. Different meta-analysis, review articles and more than 350 studies have 
reported its efficacy (when used alone or in combination with other antihyperglycemic medi-
cations, including metformin), safety profile, cardiovascular, weight reduction, metabolic 
and other benefits [43–48]. Metformin or acarbose is recommended by International Diabetes 
Federation and American Association of Clinical Endocrinologist when the lifestyle modifi-
cation strategy is not enough for prevention of type 2 diabetes [21, 49]. Acarbose can also be 
considered to be used as a first-line antihyperglycemic agent [46, 48].
Gastrointestinal side effects have been an issue with acarbose. The predominant gastrointesti-
nal symptom associated with acarbose is flatulence; however, loose stools and/or abdominal 
discomfort have also been reported. The side effects occur maximally during the first 2 weeks 
of therapy and start decreasing. By 12 weeks, 13.7% report flatulence and 2.2% diarrhea, and a 
5-year surveillance study of about 2000 patients with diabetes found that gastrointestinal side 
effects associated with acarbose were reported by only 3.9% of patients [45]. For administra-
tion and dose adjustment and for understanding its metabolic benefits, its unique mode of 
action, not just alpha-glucosidase inhibition, need to be considered.
• The effect of acarbose is to delay the digestion of starch and oligosaccharides in the small 
intestine so that the release and absorption of glucose takes place over a longer time across 
the length of the small intestine. In many individuals, alpha-glucosidases are most active 
in the upper small intestine, and as acarbose treatment continues, there is a compensatory 
increase in enzyme activity in the lower small intestine and gastrointestinal side effects 
decrease over time [45].
• Furthermore, exposure of the lower small intestine to undigested carbohydrate leads to an 
increased quantity and duration of glucagon-like peptide-1 (GLP-1) release [45]. Acarbose 
also potentiates the reduction of ghrelin [46], thus may help to increase satiety.
• Low glycemic foods are preferred in type 2 diabetes. Low glycemic index foods are created 
by different processing methods; alpha-glucosidase inhibitors mimic these compounds in that 
they decrease the glycemic index (as well as the glycemic load) of carbohydrate-rich foods [46].
• Acarbose acts by competitive inhibition of alpha-glucosidase, so it is given at the same time 
as the ingested carbohydrate [45]. When taken as a tablet, the usual available form, it is less 
effective than when consumed in powdered form; so it is better to chew the tablet with food 
than to swallow at the beginning of a meal [47].
• Acarbose blocks and slows the digestion of complex carbohydrate, like starch, and sucrose 
(table sugar) without affecting the absorption of monosaccharides like glucose and fructose 
(present in fruits) and disaccharide lactose (present in milk products), which is digested by 
beta-glucosidase [44–47]. Trials in some countries report a higher incidence of gastrointestinal 
symptoms when initiating the dose of acarbose [46]. It may be due to the dietary habit of the 
population using sugar-rich food or soft drinks with or after meals. In any case, while initiating 
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therapy with acarbose, starting with low dose (e.g. 25 mg or in a few cases still lower, once a 
day after dinner) and with slow stepwise-increasing dose over weeks avoiding the sugar-rich 
food or soft drinks with or after meals may help the patient to tolerate acarbose. Cochrane 
review reports that acarbose dosages higher than 50 mg three times daily offer no additional 
effect on HbA1c but more adverse effects instead. However, the fasting and post-load glucose 
may benefit from higher dosages [43].
Thus considering the benefits and safety of acarbose, it can be used in the treatment of dia-
betes next after metformin even if HbA1c is well controlled. With judicious initiation of the 
drug, most patients may be able to tolerate the drug. As in the case of metformin, those who 
tolerate the drug will be benefitted.
8. Principles of planning of antihyperglycemic therapy
Apart from various factors (Figure 3) to consider while prescribing antihyperglycemic medi-
cations, there are other principles to guide planning of antihyperglycemic therapy in type 2 
diabetes.
8.1. Possible loss of excess bodyweight for as long as possible and regular physical 
activity and exercise: The cornerstones of therapy of diabetes
Loss of excess body weight and maintaining regular physical activity and exercise reduce 
insulin resistance and beta-cell workload and also benefit cardiovascular health and are thus 
the cornerstones of therapy of diabetes. The medications which support such aspects are 
preferred.
8.2. Requirement of combination therapy
Combination therapy, even in many newly diagnosed diabetic patients, is often required and 
it may also allow the use of submaximal doses of each antihyperglycemic medication result-
ing in fewer side effects [41, 42].
8.3. Need of gradual building up of the doses of metformin and acarbose
The doses of antihyperglycemic medications, particularly of metformin and acarbose hav-
ing longer history of safety profile and other benefits, have to be built up slowly so that 
the patients tolerate the drugs; their maximum effect may take some time to be clinically 
evident.
8.4. ‘Dynamic dose management of medications likely to cause hypoglycemia’
There is often need of controlling blood glucose immediately to prevent or treat acute com-
plications [50]. Sulfonylurea and insulin act relatively fast. Insulin remains effective in all 
situations and it also helps to prevent ketosis. During the infection, other complications or 
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immobility of the patients or the initial stage of diagnosis, rapid control of high blood glucose 
may thus be required to be done as rescue therapy. However, sulfonylurea, repaglinide and 
insulin not only cause hypoglycemia but also prevent the patients to lose weight and may 
even cause weight gain. Normalizing blood glucose is important, but there are other factors to 
consider as well (Figure 3 ). Moreover, even if sulfonylurea is continued to control the blood 
glucose, the glucose-lowering effect of sulfonylurea by beta-cell stimulation is not durable 
and wane over some years [41, 42]. DeFronzo has pointed out that such focus on simply 
HbA1c reduction with continuous use of sulfonylurea may lead to ‘treat to fail’ approach and 
thus underlying pathophysiology also needs to be considered [41, 42]. The aim in the man-
agement of hyperglycemia in type 2 diabetes is to normalize it for as long as possible with 
the help of antihyperglycemic medications avoiding hypoglycemia and helping the patient to 
continue regular physical activity and exercise and to reduce excess bodyweight for as long 
Phases of therapy Diet, physical  
activity and exercise 
and weight plan
+ Regular use of  
antihyperglycemic  
medicines
± Temporary use of other 
antihyperglycemic  
drugs likely to cause  
hypoglycemia*
1. Initiation of therapy Recommended diet, 
reduction of excess 
body weight and 
regular physical 
activity and exercise
+ Gradually building up of 
metformin dose to the optimum 
level
± Short-term temporary use 
of sulfonylurea or insulin 
to control hyperglycemia 
immediately as rescue 
therapy
2. Once the dose of 
metformin is optimum & 
tolerable, next phase of 
therapy with other 2nd 
to 4th drugs unlikely to 
cause hypoglycemia†,‡
Continue above 
diet, physical 
activity and exercise 
and weight plan
+ Addition of acarbose, 
pioglitazone, dipeptidyl 
peptidase-4 inhibitor, glucagon-
like peptide-1 receptor agonist, 
sodium–glucose cotransporter 
2 inhibitors
± Short-term temporary use 
of sulfonylurea or insulin 
to control hyperglycemia 
immediately as rescue 
therapy
3. Regular hypoglycemic 
therapy
Continue diet and 
physical activity 
and exercise plan
+ Repaglinide, sulfonylurea or 
basal insulin with other drugs
± Short-term temporary 
use insulin to control 
hyperglycemia im mediately 
as rescue therapy
4. Long-term 
combination insulin 
therapy phase
Continue diet and 
physical activity 
and exercise plan
+ Combination insulin therapy with or without other drugs
Note: The medications are used if not contraindicated and as per their effectiveness, tolerance by patients and local guidelines.
*‘Dynamic dose adjustment of medications likely to cause hypoglycemia’ aims to taper off the dosage of the drugs like 
sulfonylurea to continue normalization of HbA1c for long time with diet, regular physical activity and exercise and 
possible loss of excess bodyweight for as long as possible and with other drugs not likely to cause hypoglycemia.
†Even if HbA1c is well controlled, considering the long-term safety profile, mechanisms of action and negligible 
systemic absorption, acarbose can be added once the optimum dose of metformin is tolerated. Acarbose is started 
with low and slow stepwise-increasing dose over weeks or months to the optimum tolerable level. In patients only on 
antihyperglycemic drugs unlikely to cause hypoglycemia, they may have their major meals two times a day as per their 
convenience and custom. In such patients, the dose of acarbose can be gradually increased to the optimum tolerable 
level, e.g. 50–100 mg two times daily with the meals. Whatever the dose the patients tolerate, it is likely to be beneficial 
considering its unique mode of action and long-term safety profile.
‡Whether to add other new drug even if blood glucose is well controlled and which one to add as 3rd or 4th drug will 
depend on various factors as discussed in the text and on the guidelines of the local regulatory bodies.
Table 1. A suggested algorithm of antihyperglycemic therapy in type 2 diabetes.
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as possible. Physical activity and exercise increases glucose utilization and reduces blood 
glucose. Thus, there is need of continuous effort to reduce the dose of sulfonylurea, repa-
glinide and insulin to the lowest possible level as the ‘Dynamic dose management of medications 
likely to cause hypoglycemia’ letting the healthy lifestyle and other non-hypoglycemic antihy-
perglycemic drugs to maintain the blood glucose [50]. Patient education and guidance from 
family physicians, diabetes educators and other health care workers will help to achieve such 
dynamic dose management.
8.5. Long-term safety profile
Geoffrey Rose rightly highlighted ‘Safety is paramount with long-term interventions’ [9]. 
There is relatively longer history of safety profile with metformin and acarbose. They are 
preferred in the prevention and in the early phase of treatment of diabetes so that they can be 
safely continued for long time.
Based on such principles, a suggested approach of antihyperglycemic therapy is outlined in 
algorithm in Table 1.
Compared to the two agents prescribed separately, combination tablets reduce pill bur-
den and help adherence of patients [49]. However due to the contrasting effect as well as 
the need of ‘dynamic dose adjustment of medications likely to cause hypoglycemia’ to the 
lowest possible dose and of gradual building of the dose of metformin for its continued 
maintenance at the optimum level, the formulation of fixed dose of combination of such 
drugs in a single tablet is irrational (Table 2) [50]. Availability of such fixed dose combina-
tion formulation in the market is likely to lead to the continued usage of sulfonylurea and 
suboptimal dosage of metformin even right from the time of diabetes diagnosis with all its 
effects in the patients.
Metformin Sulfonylurea or repaglinide
Hypoglycemia risk Neutral Moderate to severe
Effect on bodyweight Slight loss Gain
Major cardiovascular events Beneficial Generally neutral*
Principle of use To maintain optimum dose To keep the dose as minimum as possible to 
minimize hypoglycemia
Administration Usually after meal Usually before meal†
Dose adjustment with 
combination tablet
Difficult and the dose is likely to 
be suboptimal due to the fear of 
inducing hypoglycemia
Difficult and likely to cause hypoglycemia if 
the optimal dose of metformin is targeted or 
maintained
*Apart from the risk of effect of severe hypoglycemia on heart, it is also advised that use of the sulfonylurea types 
(glibenclamide, glipizide, glimepiride and others) that bind the sulfonylurea receptor-2 A and B should be avoided in 
high-risk patients suspected of having significant coronary artery disease [51].
†Sulfonylureas are often advised to be taken at least 15–20 minutes before a meal [51].
Table 2. The contrasting effect and uses of metformin and sulfonylurea and repaglinide making their fixed dose 
combination formulation irrational.
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9. Avoiding unnecessary medicines and products
There is no clear evidence that dietary supplementation with vitamins, minerals, herbs or 
spices can improve outcomes in people with diabetes who do not have underlying defi-
ciencies, and there may be safety concerns regarding their long-term use [25]. Unnecessary 
medication or local herbal, traditional or plant products may increase the cost and/or num-
ber of tablets to be taken which can affect the adherence to the essential medicines. Any 
medications or various products are also some form of chemicals and can also cause side 
effects, affect different organ systems or interact with other medications [52]. It is a famous 
saying ‘Everything under the sun, including the sun, can cause allergy or side-effects’. For 
example, peripheral edema may occur in up to 16% with pregabalin [53]; however, amlo-
dipine, a useful and essential medicine for hypertension, may instead be inadvertently 
stopped due to its well-known association with peripheral edema. Symptoms like tingling, 
numbness or others may need to be investigated. However, if treatment does not change 
the course of the condition and if symptoms do not affect sleep or daily life of the patients, 
explanation and reassurance with the required follow-up may be preferred than using 
unnecessary medications.
10. Education to the patient and training of educators
Structured education is an integral part of diabetes care [39]. Lifestyle management is a fun-
damental aspect of diabetes care and includes diabetes self-management education, diabetes 
self-management support, nutrition therapy, physical activity, smoking cessation counsel-
ing and psychosocial care [25]. Nurses and other healthcare professionals requires adequate 
training and certification to work in the health system to fill the gap between medical profes-
sionals and patients and thus between the available scientific knowledge and effective appli-
cation by the patients [50].
Research perspectives: State may develop some support system (e.g. by making available research funds or by 
involving pharmaceutical companies or other donor agencies) to study the local herbal, traditional or plant products 
and to identify and isolate the active the pharmacological ingredient of such possible crude products [52].
Public health perspectives: For the training in the management and education of people with diabetes, the nurses 
and other healthcare professionals (with minimum of 2 years of professional practice experience) should have at 
least 1000 hours of practice experience in diabetes self-management education along with various educational activi-
ties [54]. In the non-industrialized countries, it may thus entail 1 year of working under the supervision of physicians 
(as a sort of residential training) in the daily diabetes and other outdoor and indoor services providing care and edu-
cation to the patients fulfilling the other training requirements (like logbook recordings of case history records, pro-
cedure and academic activities, assignments and assessments) [50, 55]. To incorporate such trained personnel in the 
local health system, the terminology of certification of such training should match with the nomenclatures of other 
existing healthcare workers and with the various intervention programs being planned and/or implemented [55].
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11. Programmes to control diabetes epidemic
There are extensive work done and literature available regarding the diabetes epidemiol-
ogy, healthy lifestyle, primary prevention of diabetes and effects of gestational diabetes 
and in utero malnutrition and hyperglycemia. Many of them have been cited in the vari-
ous publications referred in this chapter [1–3, 7, 10, 25, 27, 29, 32, 39, 49, 56, 57, 67, 68]. 
In this section, the focus is on briefly highlighting the urgent priority public health pro-
grammes required to control the diabetes epidemic. The perspectives on controlling the 
diabetes epidemic in the population as a whole, not just primary prevention of diabetes 
in  individuals, and the implementations of the required programmes are the dire needs 
today.
11.1. Factors fueling the diabetes epidemic
The epidemic of glucose intolerance in the world is relatively a new phenomenon starting 
since the latter half of twentieth century and the initial rise in diabetes prevalence has occurred 
differently in various populations in the world [56, 57]. For example, gradual rise in diabetes 
prevalence has occurred in Europids in Europe, Canada and the USA since around 1940s 
with increasing sedentary life, obesity and aging with about a third of their population over 
50 years of age. On the top of similar gradual rise, the migrant or urbanized Asian-Indian, 
Arab, African, Chinese and Hispanic people faced the rapid rise of diabetes prevalence since 
around 1970s mostly due to the rapid transition in the nutritional status of population lead-
ing to dissociation in metabolic states of fetal life (associated with nutritional want) and adult 
life (with nutritional surfeit) of people. The indigenous people of the USA, Canada, Australia 
and Pacific region also faced the rapid rise in diabetes prevalence (due to the rapid transition 
in their nutritional status) since around 1940s and subsequently further faced the accelerated 
rise mostly due to the addition of the factor of maternal hyperglycemia during pregnancy 
affecting the in utero life of the offspring [56].
Such variations in the rise in diabetes prevalence in different populations can just be 
ascribed to the effect of ethnic variations leading to a sense of fatalism. The concept of 
ethnicity does provide self-identification with cultural traditions and social identity and 
boundaries between groups, but it has dynamic nature [58]. Ethnicity is a sort of surrogate 
marker for multiple environmental and genetic factors (though genetics playing a rela-
tively small part), in disease causation and for public health policy [56, 59, 60]. In terms 
of the scientific approach and public health policy, ethnic variations in the prevalence of 
any disease or condition should lead the humankind to search for such environmental or 
genetic factors [59]. The different pattern of initial rise in diabetes prevalence in various 
populations in the world, thus, appears to be related to the various proportions of three 
groups of risk factors present in different populations. Thus, the three groups of such pos-
sible factors to consider are [56]:
• obesity, sedentary life and aging;
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• the rapid transition in the nutritional status of population leading to dissociation in meta-
bolic states of fetal life (associated with nutritional want) and adult life (with nutritional 
surfeit) of people (this factor of in utero undernutrition appears to limit the range of normal 
body mass index in adult life in such population and even in the individual person of any 
population group) and
• maternal hyperglycemia during pregnancy affecting the in utero life of the offspring.
Whatever may be the differences of the initial rise in diabetes prevalence in the world and 
its pathogenesis, the fact remains that diabetes epidemic is now increasingly affecting the 
younger and younger population. There is, thus, the need to consider all possible factors to 
control the epidemic of diabetes in all the populations.
11.2. Healthy diet and weight and regular physical activity and exercise 
at the population level
Healthy diet with proportionate intake of nutrients, body weight as per the recommended 
body mass index for the population and regular physical activity and exercise are appli-
cable to general population and people with impaired glucose intolerance, diabetes and 
CVDs [3, 10, 21, 25, 32, 39, 56].
11.3. Prevention of maternal and childhood malnutrition
Taking a life-course perspective is essential for preventing type 2 diabetes, as it is for many 
health conditions [2]. Firstborn offspring in the resource poor settings may be at increased 
risk of glucose intolerance due to the likelihood of possible maternal malnutrition during the 
first pregnancy as compared to that in later pregnancy [56, 62]. Adequate nutrition and micro- 
and macronutrient supply before and during pregnancy are the steps to reduce the risk of in 
utero malnutrition and its ill effects [27]. Good nutrition during infancy and childhood and 
adequate physical activity among children are important for the development of a healthy 
child and an adult [27].
Public health perspectives: Campaigns and programmes are required to make the people, housewives and 
children well aware of the recommended bodyweight (as required for the respective population) and the rec-
ommendations regarding the daily intake of plain water, fruit, vegetables, salt, sugar, fat (with adequate propor-
tion of mono- and poly-unsaturated and saturated fatty acid) and other nutrient avoiding the trans-fatty acid. 
Multisectoral population-based approaches, including trade and agricultural policies and the workplace-, school- 
and other setting-based interventions, for healthy diet and physical activity and exercise need to be considered 
[2, 3, 10, 56].
Public health perspectives: Pedestrians, cyclists and public transport passengers are the top three hierarchy 
groups recommended while developing transport and traffic strategies [61]. It is also essential to have campaigns 
and support system to develop various physical activity and exercise programmes at the community, school and 
various workplace levels like regular walking, games and sports, marathon running, aerobic dance and others 
[2, 3, 10, 56].
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11.4. Maintenance of optimal pre-pregnancy bodyweight: the key programme required
The diagnosis of gestational diabetes mellitus (GDM) usually made at 24–28 weeks is 
applicable for the clinical management of the women and their children during and after 
pregnancy and it may also be useful for the mothers for primary prevention of later devel-
opment of diabetes. From further public health perspectives to avoid any possible long-
term in utero effect, prevention of subclinical maternal hyperglycemia right from the time of 
conception needs to be considered [56]. The sedentary lifestyle, obesity and glucose intoler-
ance affecting relatively younger population are increasing in the community. The risk of 
maternal hyperglycemia during pregnancy has thus increased (Figure 5) [56]. The relative 
risk of developing overt GDM over the age of 35 years is 2.57 [63]. However, significant 
increase in the risk of overt GDM is reported even at age >25 years as compared to that in 
lower age [64].
The exact ‘safe’ normal level of maternal plasma glucose to prevent relative hyperglycemia 
in utero for fetus appears difficult to define. To find out such level, long period of follow-up 
is required after birth of offspring with exposure to different levels of maternal plasma glu-
cose correlating with other risk factors [56, 57]. The normal value of neonatal plasma glucose 
may give some insight. However, the limits of normal plasma glucose defining neonatal 
hypoglycemia in infants are arbitrary. Neonatal glucose concentrations may decrease after 
birth, to as low as 30 mg/dL during the first 1–2 hours after birth, and then increase to higher 
and relatively more stable concentrations, generally above 45 mg/dL by 12 hours after birth 
[65, 66]. Later, it will gradually rise to adult levels.
Considering the risks of the macrosomia development, the safe normal level of fasting 
plasma glucose during pregnancy appears to be below 80 mg/dL (4.4 mmol/L), perhaps 
Figure 5. A vicious circle of glucose intolerance in younger population and maternal hyperglycemia during pregnancy. 
*The two preventable factors from the public health and clinical management perspectives. (Figure published with minor 
modification with kind permission from JNMA2009;48;173 [56]).
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even below 75 mg/dL (4.2 mmol/L) [67, 68]. Macrosomia is to a great extent measurable but 
the fetal programming due to relative maternal hyperglycemia is difficult to assess and is 
obviously likely to be affected earlier than the overt macrosomia. Weeks 3–8 encompass 
organogenesis and major malformations in infants of diabetic mother occur during these 
periods [69]. So to protect the fetus from any possible effect of maternal hyperglycemia, 
blood glucose during the whole duration, including the early stage, of pregnancy has to 
be within the safe normal level [56, 57]. As discussed earlier that even in non-pregnant 
state, the risk of insulin resistance and diabetes in adult increases progressively upwards 
of a BMI of 20–22 kg/m2 and more than 80% of the people with diabetes live in low- and 
middle-income countries and nearly two thirds of diabetes globally are attributable to 
BMI above 21 kg/m2 [10]. Considering the inherent insulin resistance during pregnancy 
and increasing age of mother, the pre-pregnancy bodyweight should preferably around 
or below the middle of the recommended BMI for the population [56]. In Finland with 
predominant Europid population, the mean pre-pregnancy BMI of women were 21.9 and 
23.7 kg/m2 in 1960s and 2000, respectively [70]. If it increases to higher level, as in many 
other populations, the risk of glucose intolerance during pregnancy may also increase. 
Women who had a child gains extra weight than women who remained nulliparous [71] 
and the second and subsequent offspring were anticipated about a decade earlier to have 
increased risk of in utero exposure to the maternal clinical or sub-clinical hyperglycemia 
due to the increased weight of mothers [56]. A recent study indeed reported increased risk 
of GDM with increasing weight gain from first to second pregnancy [72]. In summary, 
campaign and programmes for maintenance of optimal pre-pregnancy body weight as 
per the recommended body mass index of the respective populations along with regular 
physical activity and exercise during pregnancy are the essential measures available at 
hand to prevent the possibility of maternal hyperglycemia right from the early pregnancy 
and are the urgent priority to control diabetes epidemic.
Research perspective: Long-term follow-up study of offspring with exposure to different levels of maternal 
plasma glucose correlating with other risk factors can be conducted. Possible risk of obesity and early glucose 
intolerance in both female and male offspring due to the in utero hyperglycemia could also be due to the involve-
ment of mitochondrial DNA. Exposure of mitochondrial DNA to reactive oxygen species (ROS) can lead to 
mitochondrial mutation [73]. Glucose excursions can lead to the formation of ROS, such as superoxide, which 
leads to oxidative stress in the body [74] and acute hyperglycemia can lead to oxidative stress with increase in 
the markers of oxidative damage [75–77]. Such oxidative stress due to high glucose level for the fetus during 
pregnancy can thus be postulated to lead to oxidative damage to fetal mitochondrial DNA and the offspring in 
this way may later be at increased risk of obesity and glucose intolerance. Superoxide anions, markers of oxida-
tive damage and mediators of subclinical inflammation can be analyzed in the fetal, amniotic and/or maternal 
samples. If it is such mitochondrial inheritance as postulated, the affected female offspring would transmit the 
disease to all their children, and affected male offspring, however, would not transmit the disease to their chil-
dren. The possibility of such pattern can be studied in the populations with high prevalence of type 2 diabetes 
in young age.
Public health perspectives: Examples of prevention and control programmes in the communicable diseases as a 
model for similar strategies required at individual and population levels for diabetes epidemic are summarized 
[78] in Table 3. Control programme to protect the other susceptible populations (Table 3) is the dire need today to 
control diabetes epidemic.
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12. Conclusion
Adequate control of blood pressure, use of statin, cessation of tobacco use, regular physical 
activity and exercise and possible loss of excess bodyweight for as long as possible are the core 
management aspects in diabetes. Judicious use of antihyperglycemic drugs requires consid-
eration of various factors, especially hypoglycemia and effect on bodyweight and cardiovas-
cular events. The aim should also be to achieve normalization of HbA1c for long time by loss 
of excess bodyweight for as long as possible, regular physical activity and exercise and using 
regularly the antihyperglycemic medications not having the risk of hypoglycemia. ‘Dynamic 
dose adjustment of medications likely to cause hypoglycemia’ helps to apply such principles 
by temporary use of sulfonylurea or insulin as rescue therapy. Apart from such clinical man-
agement and various research aspects, there are public health approaches to be considered 
as the top priority for the control of diabetes epidemic in the population. The diagnosis of 
gestational diabetes usually made at 24–28 weeks is applicable for the clinical management of 
mother and child and for possible primary prevention of diabetes later in the mother. From 
the public health perspectives, however, protection of the susceptible in utero population from 
maternal malnutrition or clinical or subclinical hyperglycemia right from the time of concep-
tion itself is particularly required to control diabetes epidemic at the population level. There is 
urgent need of campaigns and programmes for maintenance of optimal pre-pregnancy body 
weight, as per the recommended body mass index for the respective populations.
Examples in the communicable disease Examples in diabetes†
Prevention programmes 
for individuals
 • Immunization
 • Personal protective measures
 • Chemoprophylaxis
 • Population-wide and primary 
prevention programs with healthy food, 
physical activity and exercise and weight 
reduction interventions to prevent impaired 
glucose tolerance and diabetes
 • Campaign and programmes to 
help achieve the body mass index by the 
people as recommended to the respective 
populations
Control programmes 
to protect the other 
susceptible populations*
 • Isolation
 • Quarantine
 • Vector control (e.g. mosquito control 
for various diseases, cyclops control for 
guinea worm, chicken and poultry culling 
for avian influenza)
 • Treatment of case (e.g. tuberculosis) 
and carrier
Campaign and programmes for
 • Maintenance of optimal  
pre-pregnancy body weight, as per the 
recommended body mass index of the 
respective populations
 • Nutritional support for the girls and 
women of childbearing age in rural and 
poorer sections of the societies
*The vulnerable populations to be protected by the control programme of diabetes include the offspring of malnourished 
or overweight mothers during their in utero life.
†National and international health and diabetes agencies should clearly spell out the control programmes, with 
appropriate budget allocation, for the control of diabetes epidemic.
Table 3. Examples of prevention and control programmes in the communicable diseases as a model for similar strategies 
for individuals and susceptible populations in diabetes epidemic (table published with minor modification) [78].
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